

1 Multiplex SARS-CoV-2 Genotyping PCR for Population-Level Variant Screening and Epidemiologic  
2 Surveillance

3  
4 **Authors:** Hannah Wang, MD<sup>1\*</sup>; Jacob A. Miller, MD<sup>2\*</sup>; Michelle Verghese, BA<sup>1</sup>; Mamdouh Sibai, BS<sup>3</sup>;  
5 Daniel Solis, BS<sup>1</sup>; Kenji O. Mfuh, PhD<sup>3</sup>; Becky Jiang, CLS<sup>3</sup>; Naomi Iwai, CLS<sup>3</sup>; Marilyn Mar, CLS<sup>3</sup>;  
6 ChunHong Huang, MD<sup>1</sup>; Fumiko Yamamoto, MS<sup>1</sup>; Malaya K. Sahoo, PhD<sup>1</sup>; James Zehnder, MD<sup>1</sup>;  
7 Benjamin A. Pinsky, MD, PhD<sup>1,3,4</sup>

8  
9 \*Authors HW and JAM contributed equally to this manuscript.

10  
11 **Author Affiliations:**

12 <sup>1</sup>Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA

13 <sup>2</sup>Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA

14 <sup>3</sup>Clinical Virology Laboratory, Stanford Health Care, Stanford, CA, USA

15 <sup>4</sup>Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University  
16 School of Medicine, Stanford, CA, USA

17  
18 **Key Words:** SARS-CoV-2; COVID-19; Variant; Genotyping; RT-qPCR

19  
20 **Running Title:** SARS-CoV-2 Variant Genotyping PCR

21  
22 **Corresponding Author:**

23 Benjamin A. Pinsky, MD, PhD

24 3375 Hillview, Room 2913

25 Palo Alto, CA 94304

26 Phone (650) 498-5575

27 Fax (650) 736-1964

28 [bpinsky@stanford.edu](mailto:bpinsky@stanford.edu)

29

**Alternate Corresponding Author:**

Hannah Wang, MD

3375 Hillview, Room 2913

Palo Alto, CA 94304

Phone (650) 498-5575

Fax (650) 736-1964

[wangh1@stanford.edu](mailto:wangh1@stanford.edu)

30 **Summary / Key Points:**

31 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.  
32 Emergence of SARS-CoV-2 variants with concerning phenotypes is of public health interest. We  
33 developed a multiplex genotyping RT-qPCR to rapidly detect L452R, E484K, and N501Y with high  
34 sequencing concordance. This high-throughput alternative to resource-intensive sequencing enabled  
surveillance of L452R emergence.

35 **ABSTRACT:**

36

37 **Background:** Emergence of SARS-CoV-2 variants with concerning phenotypic mutations is of public  
38 health interest. Genomic surveillance is an important tool for pandemic response, but many laboratories  
39 do not have the resources to support population-level sequencing. We hypothesized that a spike  
40 genotyping nucleic acid amplification test (NAAT) could facilitate high-throughput variant surveillance.

41

42 **Methods:** We designed and analytically validated a one-step multiplex allele-specific reverse  
43 transcriptase polymerase chain reaction (RT-qPCR) to detect three non-synonymous spike protein  
44 mutations (L452R, E484K, N501Y). Assay specificity was validated with next-generation whole-genome  
45 sequencing. We then screened a large cohort of SARS-CoV-2 positive specimens from our San  
46 Francisco Bay Area population.

47

48 **Results:** Between December 1, 2020 and March 1, 2021, we screened 4,049 unique infections by  
49 genotyping RT-qPCR, with an assay failure rate of 2.8%. We detected 1,567 L452R mutations (38.7%),  
50 34 N501Y mutations (0.84%), 22 E484K mutations (0.54%), and 3 (0.07%) E484K+N501Y mutations.  
51 The assay had near-perfect (98-100%) concordance with whole-genome sequencing in a validation  
52 subset of 229 specimens, and detected B.1.1.7, B.1.351, B.1.427, B.1.429, B.1.526, and P.2 variants,  
53 among others. The assay revealed rapid emergence of L452R in our population, with a prevalence of  
54 24.8% in December 2020 that increased to 62.5% in March 2021.

55

56 **Conclusions:** We developed and clinically implemented a genotyping RT-qPCR to conduct high-  
57 throughput SARS-CoV-2 variant screening. This approach can be adapted for emerging mutations and  
58 immediately implemented in laboratories already performing NAAT worldwide using existing equipment,  
59 personnel, and extracted nucleic acid.

## 60 INTRODUCTION

61  
62 High transmission rates during the coronavirus disease 2019 (COVID-19) pandemic have facilitated the  
63 emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. The underlying  
64 genomic diversity defining these variants is indicative of natural selection of mutations with phenotypic  
65 significance.<sup>1-3</sup> In particular, variants associated with increased transmission, virulence, or resistance to  
66 host, vaccine, or antiviral immunity are of significant public health concern.<sup>4-17</sup> Other mutations could also  
67 potentially impact diagnostic sensitivity.<sup>18</sup> Genomic surveillance that is representative of the newly-  
68 infected population is therefore an important tool for pandemic response.

69  
70 As of March 2021, the United States Centers for Disease Control and Prevention (CDC), European  
71 Centre for Disease Prevention and Control (ECDC), and World Health Organization (WHO) identified  
72 multiple SARS-CoV-2 lineages as variants of concern or variants of interest (VOC/VOI).<sup>19-21</sup> Many share  
73 the spike protein mutations E484K (B.1.351, B.1.525, B.1.526, P.1, P.2), N501Y (B.1.1.7, B.1.351, P.1),  
74 and/or L452R (B.1.427, B.1.429), among others. Such variants have primarily been identified by targeted  
75 or whole-genome sequencing. However, due to the required resources, technical expertise, and  
76 equipment for sequencing, few public health systems have successfully coordinated timely large-scale  
77 sequencing efforts. Among individual institutions that have developed sequencing programs, there is  
78 tremendous variability in throughput, selection criteria, and methodology that confound accurate  
79 estimates of individual variant prevalence. Because the vast majority of laboratories worldwide do not  
80 have the resources required to develop and support large-scale sequencing initiatives, a complementary  
81 surveillance strategy is desirable.

82  
83 Upper respiratory nucleic acid amplification tests (NAATs) are the mainstay of SARS-CoV-2 diagnosis. In  
84 contrast to sequencing, nearly all laboratories offering NAATs have equipment and trained personnel for  
85 nucleic acid extraction and real-time polymerase chain reaction. We therefore aimed to develop a highly-  
86 accessible spike genotyping NAAT for high-throughput and rapid screening of positive SARS-CoV-2  
87 samples. We hypothesized that this assay would facilitate large-scale VOC/VOI screening and track  
88 emergence of mutations in our population. This approach enables population-based triaging of samples  
89 to centers performing sequencing analysis for lineage determination and increases access to variant  
90 surveillance.

## 91 92 METHODS:

### 93 94 *Assay Design*

95 In January 2021, the B.1.1.7, B.1.351, B.1.1.28 descendant P.1, B.1.1.28 descendant P.2, and  
96 B.1.427/B.1.429 variant lineages were of primary global and local epidemiologic significance. Informed by  
97 recent studies describing mutation phenotypic significance and convergent evolution, we elected to begin

98 screening our population for the spike N501Y (B.1.1.7, B.1.351, P.1), E484K (B.1.351, P.1, P.2), and  
99 L452R (B.1.427/B.1.429) mutations.

100

101 We therefore designed a one-step multiplex allele-specific reverse transcriptase quantitative polymerase  
102 chain reaction (RT-qPCR) to detect these three non-synonymous single nucleotide variants in the spike  
103 gene (N501Y: RefSeq NC\_045512 23063A>T; E484K: 23012G>A, L452R: 22917 T>G). We selected the  
104 wild-type N501 allele (23063A) to serve as a control for those samples that lack any of the targeted  
105 mutations.

106

107 To permit single reaction multiplexing, we designed primer sets and dual-labeled hydrolysis probes to  
108 maximize each probe's mismatch- $\Delta T_m$  while maintaining probe specificity and a sufficiently high  
109 annealing temperature (Supplementary Table 1). This 2-7°C decrease in each probe's annealing  
110 temperature ( $\Delta T_m$ ) when binding SARS-CoV-2 cDNA with a single nucleotide mismatch distinguishes  
111 mutant from wild-type nucleic acid templates. Given the proximity between the E484K and N501Y  
112 mutations, two primer sets (flanking L452R and E484K/N501Y, respectively) were designed with  
113 annealing temperatures similar to or above probe annealing temperatures.

114

115 Recognizing the potential for mutations in the targets, on January 26, 2021 we downloaded all available  
116 SARS-CoV-2 sequences from GISAID annotated as B.1.1.7 (n=7,864), B.1.351 (n=341), or  
117 B.1.427/B.1.429 variants (n=622), as well as all available sequences from NCBI collected prior to  
118 December 2020 (n=31,016).<sup>22</sup> Primer sequences were conserved in >98.8% of all sequences; mutant  
119 probe sequences were conserved in >99.7% of variant-specific sequences and were present in only 0.1%  
120 of pre-December 2020 NCBI sequences. The wild-type N501 probe sequence was conserved in 99.2% of  
121 pre-December 2020 NCBI sequences.

122

123 Additional details regarding synthetic controls, oligonucleotides, cycling conditions, fluorescence  
124 thresholds, analytical validation, and assay interpretation for reporting are provided in the Supplementary  
125 Methods, Supplementary Tables 1-6, and Supplemental Figure 1.

126

### 127 *Clinical Specimens*

128 This study included upper respiratory swab specimens collected between December 1, 2020 and March  
129 3, 2021 from patients as part of routine clinical care. All specimens testing positive for SARS-CoV-2 by  
130 NAAT with RT-qPCR  $C_t \leq 30$  or transcription-mediated amplification relative light units (RLU)  $\geq 1,100$   
131 during this period were subject to multiplex allele-specific genotyping RT-qPCR. All tests were conducted  
132 at the Stanford Clinical Virology Laboratory, which serves tertiary-care academic hospitals and affiliated  
133 outpatient facilities in the San Francisco Bay Area. After development and analytical validation of our  
134 genotyping RT-qPCR, we retrospectively screened all eligible positive specimens dating back to  
135 December 1, 2020, and then began prospective genotyping on February 19, 2021. This study was

136 conducted with Stanford institutional review board approval (protocol 48973), and individual consent was  
137 waived.

138

139 Prior to genotyping RT-qPCR, initial respiratory SARS-CoV-2 NAAT was conducted on a variety of  
140 platforms (Table 1, Supplementary Methods).<sup>23–25</sup> All assays were conducted according to manufacturer  
141 and emergency authorization instructions.<sup>26,27</sup>

142

#### 143 *Assay Validation with Next-Generation Sequencing*

144 A subset of wild-type and mutant specimens genotyped by RT-qPCR were confirmed by WGS in a  
145 validation dataset. We adapted an existing WGS pipeline for poliovirus genotyping to conduct SARS-  
146 CoV-2 whole-genome amplicon-based sequencing (Supplementary Methods).<sup>28–30</sup> Pangolin was used for  
147 PANGO lineage assignment, while Nextclade v0.14.2 and auspice.us 0.5.0. were used to assign  
148 Nextstrain clades and perform phylogenetic placement.<sup>2,30,31</sup> PANGO lineage names and Nextstrain clade  
149 names were assigned as of April 5, 2021.

150

#### 151 *Statistical Analysis*

152 Baseline continuous data were compared with t-tests or Wilcoxon rank-sum tests, whereas categorical  
153 data were compared with Fisher exact tests. Positive percent agreement (PPA) and negative percent  
154 agreement (NPA) were reported with Clopper-Pearson score 95% binomial confidence intervals using  
155 next-generation sequencing as the reference method. Analyses were conducted using the R statistical  
156 software package. This study was reported in accordance with STARD guidelines.<sup>32</sup>

157

## 158 **RESULTS**

159

#### 160 *Population-Level Screening Results*

161 During the period between December 1, 2020 and March 3, 2021, our clinical virology laboratory reported  
162 165,501 negative and 13,083 positive SARS-CoV-2 NAATs among 119,154 unique patients. These  
163 13,083 positive NAATs corresponded to 11,635 patients (Table 1). We assumed this reflected  
164 approximately 11,635 unique infections, presuming no re-infection during the study period.

165

166 After triaging specimens with higher viral load and sufficient remaining material, we screened 4,049  
167 specimens from unique patients by genotyping RT-qPCR (Table 1, Figure 1). Amplification curves from  
168 RT-qPCR were interpreted according to Supplementary Table 4, with example cases presented in  
169 Supplementary Figure 2. A total of 174 specimens had amplification failure on initial RT-qPCR, either due  
170 to low viral load, amplification failure, or reaction setup error. Among these specimens, 59 were  
171 successfully genotyped on repeat RT-qPCR and are included in the analysis dataset, while the remaining  
172 115 were unable to genotype, corresponding to an assay failure rate of 2.8%. Among initial diagnostic

173 specimens tested by RT-qPCR with available  $C_t$  values (3,142), median viral load was significantly lower  
174 among samples unable to genotype ( $C_t$  28.8 vs 18.8,  $p < 0.001$ ).

175

176 Among the 3,934 genotyped specimens, we identified 1,567 (38.7%) with isolated L452R mutations, 34  
177 (0.84%) with isolated N501Y mutations, 22 (0.54%) with isolated E484K mutations, and 3 (0.07%) with  
178 E484K+N501Y mutations.

179

#### 180 *Assay Validation with Next-Generation Sequencing*

181 In addition to validating the assay's analytical performance (Supplementary Tables 5-6), we assessed  
182 clinical positive (PPA) and negative percent agreement (NPA) of genotyping RT-qPCR using WGS as a  
183 reference method. Among 229 specimens from unique patients assessed by both RT-qPCR and WGS  
184 (Table 1), PPA of RT-qPCR for L452R, E484K, and N501Y were: 100% (95% CI 95-100%), 100% (95%  
185 CI 80-100%), and 100% (95% CI 86-100%), respectively (Table 2). There were no false negatives by RT-  
186 qPCR for L452R, E484K, or N501Y. Furthermore, there were no false positives for E484K (NPA: 100%,  
187 95% CI 98-100%) or N501Y (NPA: 100%, 95% CI 98-100%).

188

189 There were three specimens positive for L452R by RT-qPCR but negative for by WGS (NPA: 98%, 95%  
190 CI 95-99%). These had L452R  $C_t$  values of 20.0, 22.8, and 31.2 with appropriate amplification curves and  
191 appropriate N501 wild-type (Cy3.5) internal control amplification ( $C_t$  21.0, 18.4, 30.0). Sequencing  
192 coverage and codon calls at the L452 loci were 1,890/1,907 (99%), 2,407/2,424 (99%), and 2,817/2,841  
193 (99%) for these three specimens, which were assigned lineages of B.1.1.222, B.1.2, and B.1.243,  
194 respectively. All three specimens were re-extracted and repeated by RT-qPCR with the same result.

195

196 Among the 229 specimens tested by both RT-qPCR and WGS, the distribution of PANGO lineages is  
197 presented in Table 3, and a phylogenetic tree of Nextstrain clades is presented in Figure 2. The 120  
198 specimens which were wild-type by RT-qPCR were most commonly assigned lineages of B.1.2 (34%)  
199 and B.1 (12%). Among the 70 specimens with isolated L452 mutations by RT-qPCR, 43 (60%) and 23  
200 (33%) were B.1.427 and B.1.429, respectively. Among the 22 specimens with isolated N501Y mutations  
201 by RT-qPCR, 17 (77%) were B.1.1.7. Among the 14 specimens with isolated E484K mutations by RT-  
202 qPCR, 11 (79%) were P.2, 2 (14%) were B.1, and 1 (7%) was B.1.526 (Figure 3). The three specimens  
203 with E484K+N501Y mutations were all of B.1.351 lineage. Sequencing quality measures and GISAID  
204 accessions are provided in Supplementary Tables 7-8.

205

#### 206 *Epidemiologic Emergence of L452R*

207 During the study period, we observed rapid emergence of the L452R mutation in our population (Figure 4,  
208 Table 4). The majority of such specimens assessed by WGS were B.1.427/B.1.429 variants (93%).

209 Although the number of new infections in our population decreased between January and March 2021,



210 the proportion of new infections harboring the L452R mutation increased from 24.8% in December 2020  
211 to 62.5% in March 2021.

212

## 213 **DISCUSSION**

214

215 Rapid, accessible, and high-throughput epidemiologic surveillance for SARS-CoV-2 variants is of public  
216 health interest. We describe a one-step multiplex RT-qPCR assay that facilitated screening of  
217 approximately 4,000 unique infections during a period of high transmission in the San Francisco Bay  
218 Area. This assay had excellent concordance with WGS and revealed rapid emergence of variants  
219 harboring L452R. In contrast to WGS, the widely-available equipment, resources, and trained personnel  
220 make this RT-qPCR assay accessible to nearly all laboratories already offering SARS-CoV-2 NAATs. All  
221 current CDC-classified variants of concern (B.1.1.7, P.1, B.1.351, B.1.427, B.1.429) and most variants of  
222 interest (P.2, B.1.525, some but not all B.1.526) harbor at least one of the L452R, E484K, or N501Y spike  
223 protein mutations, enabling population-level triaging by RT-qPCR to centers performing WGS for lineage  
224 determination. This approach has implications for outbreak surveillance, diagnostic testing,  
225 transmissibility, virulence, and vaccine and/or antiviral efficacy.

226

227 The CDC, ECDC, and WHO have identified multiple SARS-CoV-2 lineages as variants of concern (VOC)  
228 or variants of interest (VOI).<sup>19-21</sup> Many of these variants share the E484K mutation (B.1.351, B.1.525,  
229 some B.1.526, P.1, P.2), N501Y mutation (B.1.1.7, B.1.351, P.1), and/or the L452R mutation (B.1.427,  
230 B.1.429). Previously-reported studies guided by large-scale genomic surveillance have suggested  
231 increased transmissibility, virulence, or reduced vaccine/antiviral efficacy/neutralization corresponding to  
232 the phenotypic significance of these spike protein mutations.<sup>4-17</sup> Moreover, mutations in the spike gene (S  
233 gene) may lead to false negative NAAT results.<sup>18</sup>

234

235 While whole-genome sequencing is required to confirm infection with a specific variant, not all centers  
236 have the required resources or personnel to conduct large-scale variant genotyping on a high proportion  
237 of incident cases. Allele-specific NAAT-based methods are an alternative to large-scale sequencing  
238 programs, but few methods have been described. Korukluoglu et al. recently described a one-step RT-  
239 qPCR assay to detect the N501Y and HVdel69-70 using allele-specific forward primers, reserving  
240 ORF1ab as an internal control.<sup>33</sup> This assay is conducted in two separate reactions, with the first targeting  
241 N501, ORF1ab, and HV69-70del, while the second amplifies N501Y, ORF1ab, and HV69-70del. The  
242 authors described high concordance (100%) with Sanger and next-generation sequencing. A  
243 disadvantage of this method is the absence of screening for E484K and the requirement for two separate  
244 reactions. More recently, Banada et al. reported an RT-qPCR method for detection of N501Y using melt  
245 curve analysis.<sup>34</sup> This assay includes allele-specific molecular beacon probes for N501 and N501Y  
246 conjugated to different fluorophores, similar to our assay. Twenty patient specimens were tested and a  
247 subset were confirmed by Sanger sequencing.

248

249 Vogels et al. have also described an RT-qPCR assay to detect the ORF1ab 3675-3677 and spike HV69-  
250 70 deletions.<sup>35</sup> The deletions are detected via ORF1ab-Cy5 and spike-HEX probe dropout, reserving the  
251 CDC N1 primer/probe set as an internal control. This assay was concordant with 76 sequenced  
252 specimens. Limitations of this assay, as described by the authors, are N1-FAM autofluorescence leading  
253 to false B.1.1.7 drop-out and absence of the ORF1ab 3675-3677 deletion in select B.1.351 isolates. While  
254 these deletions are surrogates for B.1.1.7, B.1.351, and P.1, screening for N501Y and E484K may be  
255 more specific to variants of concern/interest and appear to be causally-associated with concerning  
256 phenotypes. Another genotyping NAAT utilized a two-step approach combining the CDC-based  
257 laboratory-developed RT-qPCR and the ThermoFisher TaqPath COVID-19 RT-PCR.<sup>36</sup> With the intent to  
258 identify B.1.1.7 variants, the authors screened 1,035 samples for TaqPath S gene dropout and genotyped  
259 two specimens by multiplex droplet digital PCR amplifying HV69-70del, N501Y, del145, and S982A in two  
260 reactions, which were positive for these four mutations. Next-generation sequencing confirmed B.1.1.7  
261 lineage. Limitations of this genotyping approach include dependence upon S gene dropout followed by  
262 more labor-intensive ddPCR.

263

264 The largest NAAT-based genotyping series thus far was a national effort in France recently reported by  
265 Haim-Boukobza et al.<sup>37</sup> The authors used two separate assays to screen for the HVdel69-70 and N501Y  
266 mutations in 35,208 samples, with an uninterpretable assay rate of 19.0% and sequencing concordance  
267 Kappa coefficient of 0.87-0.88.

268

269 To our knowledge, the present study is the largest NAAT-based SARS-CoV-2 genotyping initiative in the  
270 United States. While large multi-institutional programs such as the United Kingdom COVID-19 genomics  
271 consortium have sequenced more than 250,000 specimens, many public health systems or private  
272 institutions are unable to conduct high-throughput genotyping due to the required cost, equipment, and  
273 expertise. The RT-qPCR assay we describe is accessible to any laboratory conducting RT-qPCR SARS-  
274 CoV-2 testing, and shares much of the same equipment and reagents. Specimens positive for SARS-  
275 CoV-2 by initial NAAT can be rapidly genotyped within hours using the same extracted nucleic acid, and  
276 the cost of this assay's custom oligonucleotides are less than one U.S. Dollar per reaction. As proof of  
277 concept, we have validated this assay on various qPCR instruments and master mixes, demonstrating  
278 that individual laboratories may adapt this assay to existing NAAT workflows.

279

280 As evidence of the feasibility of high-throughput testing, we rapidly implemented reflex genotyping RT-  
281 qPCR for positive specimens and screened more than 4,000 infections, thereby facilitating local  
282 surveillance of L452R mutation emergence. Our results are consistent with a large-scale whole-genome  
283 sequencing initiative of 2,172 specimens from 44 counties in California.<sup>12</sup> This series suggested a 19-24%  
284 increase in transmissibility relative to wild-type circulating strains, and was the basis for L452R



285 surveillance in our study. Due to the local prevalence of circulating L452R mutations, our screening  
286 initiative identified approximately 1,500 unique infections harboring L452R mutations.

287

288 This assay has several limitations. Sporadic isolated L452R, E484K, and N501Y mutations are well-  
289 described and are not necessarily indicative of VOC/VOI. For example, in our series of 229 sequenced  
290 specimens genotyped by RT-qPCR, isolated E484K or N501Y mutations by PCR were VOC/VOI in 86%  
291 and 77% of cases, respectively, while the remaining were uncommon variants. Although our assay does  
292 not screen for several other mutations of interest (HVdel69-70, K417N, P681H, Y453F), it is  
293 advantageous that such variants are screen-detected via N501Y (B.1.1.7: del69-70, P681H), E484K (P.1  
294 and B.1.351: K417N), and/or L452R. An additional limitation is the lack of wild-type probes for L452 and  
295 E484. Although this choice was intentional to maximize efficiency, it introduces the possibility that  
296 synonymous or alternate non-synonymous mutations (e.g. E484Q) within the probe binding site could  
297 lead to an erroneous result. Lastly, variants may develop new mutations in primer and/or probe sites,  
298 potentially leading to false negatives. As such, these primer/probe sequences should be regularly  
299 checked against all available GISAID sequences, and new VOC/VOI should be monitored for potential  
300 assay interference. An additional limitation is exclusion of samples with lower viral load in an effort to  
301 successfully genotype. Although our assay failure rate was low (2.8%), analytical sensitivity could be  
302 improved by increasing template volume. Although the present series of 4,049 infections is a subset of  
303 the 11,635 unique consecutive infections between December 2020 and March 2021, the genotyped  
304 population was similar to the overall population (Table 1). Nevertheless, our results may not be  
305 necessarily generalizable to all new infections.

306

307 We developed and rapidly implemented a one-step multiplex allele-specific RT-qPCR assay to conduct  
308 rapid and high-throughput SARS-CoV-2 variant screening in the San Francisco Bay Area. The assay had  
309 near-perfect concordance with whole-genome next-generation sequencing and facilitates detection of all  
310 common and uncommon variants of concern/interest harboring the L452R, E484K, or N501Y mutations.  
311 This approach can be adapted for emerging mutations and implemented in laboratories already  
312 conducting SARS-CoV-2 NAAT using existing resources and extracted nucleic acid.

313

#### 314 **ACKNOWLEDGEMENTS**

315

316 We sincerely thank the Stanford Clinical Virology Laboratory staff for their dedication and commitment to  
317 patient care in the face of unprecedented challenges presented by the COVID-19 pandemic. We also  
318 thank the Stanford Protein and Nucleic Acid Facility for oligonucleotide synthesis.

319

#### 320 **FUNDING/CONFLICTS OF INTEREST**

321 The authors report no conflicts of interest related to this work.

322

## 323 REFERENCES

324

- 325 1. Korber B, Fischer WM, Gnanakaran S, et al. Tracking Changes in SARS-CoV-2 Spike: Evidence  
326 that D614G Increases Infectivity of the COVID-19 Virus. *Cell*. 2020;182(4):812-827.e19.  
327 doi:10.1016/j.cell.2020.06.043
- 328 2. Hadfield J, Megill C, Bell SM, et al. Nextstrain: real-time tracking of pathogen evolution. *Bioinforma*  
329 *Oxf Engl*. 2018;34(23):4121-4123. doi:10.1093/bioinformatics/bty407
- 330 3. Day T, Gandon S, Lion S, Otto SP. On the evolutionary epidemiology of SARS-CoV-2. *Curr Biol*.  
331 2020;30(15):R849-R857. doi:10.1016/j.cub.2020.06.031
- 332 4. Davies NG, Abbott S, Barnard RC, et al. Estimated transmissibility and impact of SARS-CoV-2  
333 lineage B.1.1.7 in England. *Science*. Published online March 3, 2021. doi:10.1126/science.abg3055
- 334 5. Galloway SE. Emergence of SARS-CoV-2 B.1.1.7 Lineage — United States, December 29, 2020–  
335 January 12, 2021. *MMWR Morb Mortal Wkly Rep*. 2021;70. doi:10.15585/mmwr.mm7003e2
- 336 6. Muik A, Wallisch A-K, Sängler B, et al. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus  
337 by BNT162b2 vaccine-elicited human sera. *Science*. 2021;371(6534):1152-1153.  
338 doi:10.1126/science.abg6105
- 339 7. Densely sampled viral trajectories suggest longer duration of acute infection with B.1.1.7 variant  
340 relative to non-B.1.1.7 SARS-CoV-2 | medRxiv. Accessed March 29, 2021.  
341 <https://www.medrxiv.org/content/10.1101/2021.02.16.21251535v1>
- 342 8. Volz E, Mishra S, Chand M, et al. Transmission of SARS-CoV-2 Lineage B.1.1.7 in England:  
343 Insights from linking epidemiological and genetic data. *medRxiv*. Published online January 4,  
344 2021:2020.12.30.20249034. doi:10.1101/2020.12.30.20249034
- 345 9. Resende PC, Gräf T, Paixão ACD, et al. A potential SARS-CoV-2 variant of interest (VOI) harboring  
346 mutation E484K in the Spike protein was identified within lineage B.1.1.33 circulating in Brazil.  
347 *bioRxiv*. Published online March 13, 2021:2021.03.12.434969. doi:10.1101/2021.03.12.434969
- 348 10. Xie X, Liu Y, Liu J, et al. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y  
349 variants by BNT162b2 vaccine-elicited sera. *Nat Med*. Published online February 8, 2021.  
350 doi:10.1038/s41591-021-01270-4
- 351 11. Phylogenetic relationship of SARS-CoV-2 sequences from Amazonas with emerging Brazilian  
352 variants harboring mutations E484K and N501Y in the Spike protein - SARS-CoV-2 coronavirus /  
353 nCoV-2019 Genomic Epidemiology. *Virological*. Published January 11, 2021. Accessed March 29,  
354 2021. [https://virological.org/t/phylogenetic-relationship-of-sars-cov-2-sequences-from-amazonas-](https://virological.org/t/phylogenetic-relationship-of-sars-cov-2-sequences-from-amazonas-with-emerging-brazilian-variants-harboring-mutations-e484k-and-n501y-in-the-spike-protein/585)  
355 [with-emerging-brazilian-variants-harboring-mutations-e484k-and-n501y-in-the-spike-protein/585](https://virological.org/t/phylogenetic-relationship-of-sars-cov-2-sequences-from-amazonas-with-emerging-brazilian-variants-harboring-mutations-e484k-and-n501y-in-the-spike-protein/585)
- 356 12. Deng X, Garcia-Knight MA, Khalid MM, et al. Transmission, infectivity, and antibody neutralization of  
357 an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation. *medRxiv*.  
358 Published online March 9, 2021:2021.03.07.21252647. doi:10.1101/2021.03.07.21252647
- 359 13. Madhi SA, Baillie V, Cutland CL, et al. Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222)  
360 Covid-19 vaccine against the B.1.351 variant in South Africa. *medRxiv*. Published online February  
361 12, 2021:2021.02.10.21251247. doi:10.1101/2021.02.10.21251247
- 362 14. Wang P, Wang M, Yu J, et al. Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody  
363 Neutralization. *bioRxiv*. Published online March 2, 2021:2021.03.01.433466.  
364 doi:10.1101/2021.03.01.433466
- 365 15. Emary KRW, Golubchik T, Aley PK, et al. *Efficacy of ChAdOx1 NCoV-19 (AZD1222) Vaccine*  
366 *Against SARS-CoV-2 VOC 202012/01 (B.1.1.7)*. Social Science Research Network; 2021.  
367 doi:10.2139/ssrn.3779160
- 368 16. Collier DA, Marco AD, Ferreira IATM, et al. SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-  
369 elicited, convalescent and monoclonal antibodies. *medRxiv*. Published online February 15,  
370 2021:2021.01.19.21249840. doi:10.1101/2021.01.19.21249840
- 371 17. Shen X, Tang H, McDanal C, et al. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing  
372 antibodies elicited by ancestral Spike vaccines. *bioRxiv*. Published online January 29,  
373 2021:2021.01.27.428516. doi:10.1101/2021.01.27.428516
- 374 18. Health C for D and R. Genetic Variants of SARS-CoV-2 May Lead to False Negative Results with  
375 Molecular Tests for Detection of SARS-CoV-2 - Letter to Clinical Laboratory Staff and Health Care  
376 Providers. *FDA*. Published online January 8, 2021. Accessed March 29, 2021.

- 377 [https://www.fda.gov/medical-devices/letters-health-care-providers/genetic-variants-sars-cov-2-may-](https://www.fda.gov/medical-devices/letters-health-care-providers/genetic-variants-sars-cov-2-may-lead-false-negative-results-molecular-tests-detection-sars-cov-2)  
378 [lead-false-negative-results-molecular-tests-detection-sars-cov-2](https://www.fda.gov/medical-devices/letters-health-care-providers/genetic-variants-sars-cov-2-may-lead-false-negative-results-molecular-tests-detection-sars-cov-2)
- 379 19. CDC. Cases, Data, and Surveillance. Centers for Disease Control and Prevention. Published  
380 February 11, 2020. Accessed March 29, 2021. [https://www.cdc.gov/coronavirus/2019-ncov/cases-](https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html)  
381 [updates/variant-surveillance/variant-info.html](https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html)
- 382 20. Risk assessment: SARS-CoV-2 - increased circulation of variants of concern and vaccine rollout in  
383 the EU/EEA, 14th update. European Centre for Disease Prevention and Control. Published  
384 February 15, 2021. Accessed March 29, 2021. [https://www.ecdc.europa.eu/en/publications-](https://www.ecdc.europa.eu/en/publications-data/covid-19-risk-assessment-variants-vaccine-fourteenth-update-february-2021)  
385 [data/covid-19-risk-assessment-variants-vaccine-fourteenth-update-february-2021](https://www.ecdc.europa.eu/en/publications-data/covid-19-risk-assessment-variants-vaccine-fourteenth-update-february-2021)
- 386 21. Weekly epidemiological update on COVID-19 - 30 March 2021. Accessed April 5, 2021.  
387 [https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---31-march-](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---31-march-2021)  
388 [2021](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---31-march-2021)
- 389 22. Elbe S, Buckland-Merrett G. Data, disease and diplomacy: GISAID's innovative contribution to  
390 global health. *Glob Chall Hoboken NJ*. 2017;1(1):33-46. doi:10.1002/gch2.1018
- 391 23. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-  
392 time RT-PCR. *Eurosurveillance*. 2020;25(3). doi:10.2807/1560-7917.ES.2020.25.3.2000045
- 393 24. Bulterys PL, Garamani N, Stevens B, et al. Comparison of a laboratory-developed test targeting the  
394 envelope gene with three nucleic acid amplification tests for detection of SARS-CoV-2. *J Clin Virol*  
395 *Off Publ Pan Am Soc Clin Virol*. 2020;129:104427. doi:10.1016/j.jcv.2020.104427
- 396 25. Hogan CA, Sahoo MK, Pinsky BA. Sample Pooling as a Strategy to Detect Community  
397 Transmission of SARS-CoV-2. *JAMA*. 2020;323(19):1967-1969. doi:10.1001/jama.2020.5445
- 398 26. In Vitro Diagnostics EUAs - Molecular Diagnostic Tests for SARS-CoV-2 | FDA. Accessed March  
399 31, 2021. [https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-](https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-2#individual-molecular)  
400 [authorizations-medical-devices/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-](https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-2#individual-molecular)  
401 [2#individual-molecular](https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-2#individual-molecular)
- 402 27. Stanford Health Care Clinical Virology Laboratory. Food and Drug Administration Emergency Use  
403 Authorization: SARS-CoV-2 RT-PCR Assay. Accessed March 14, 2021.  
404 <https://www.fda.gov/media/136818/download>.
- 405 28. Sahoo MK, Holubar M, Huang C, et al. Detection of Emerging Vaccine-Related Polioviruses by  
406 Deep Sequencing. *J Clin Microbiol*. 2017;55(7):2162-2171. doi:10.1128/JCM.00144-17
- 407 29. Quick J, Grubaugh ND, Pullan ST, et al. Multiplex PCR method for MinION and Illumina sequencing  
408 of Zika and other virus genomes directly from clinical samples. *Nat Protoc*. 2017;12(6):1261-1276.  
409 doi:10.1038/nprot.2017.066
- 410 30. Rambaut A, Holmes EC, O'Toole Á, et al. A dynamic nomenclature proposal for SARS-CoV-2  
411 lineages to assist genomic epidemiology. *Nat Microbiol*. 2020;5(11):1403-1407.  
412 doi:10.1038/s41564-020-0770-5
- 413 31. Sagulenko P, Puller V, Neher RA. TreeTime: Maximum-likelihood phylodynamic analysis. *Virus*  
414 *Evol*. 2018;4(1). doi:10.1093/ve/vex042
- 415 32. Bossuyt PM, Reitsma JB, Bruns DE, et al. STARD 2015: An Updated List of Essential Items for  
416 Reporting Diagnostic Accuracy Studies. *Radiology*. 2015;277(3):826-832.  
417 doi:10.1148/radiol.2015151516
- 418 33. Korukluoglu G, Kolukirik M, Bayrakdar F, et al. *40 Minutes RT-QPCR Assay for Screening Spike*  
419 *N501Y and HV69-70del Mutations*. *Microbiology*; 2021. doi:10.1101/2021.01.26.428302
- 420 34. Banada P, Green R, Banik S, et al. A Simple RT-PCR Melting temperature Assay to Rapidly Screen  
421 for Widely Circulating SARS-CoV-2 Variants. *medRxiv Prepr Serv Health Sci*. Published online  
422 March 8, 2021. doi:10.1101/2021.03.05.21252709
- 423 35. Vogels CBF, Breban MI, Alpert T, et al. *PCR Assay to Enhance Global Surveillance for SARS-CoV-*  
424 *2 Variants of Concern*. *Infectious Diseases (except HIV/AIDS)*; 2021.  
425 doi:10.1101/2021.01.28.21250486
- 426 36. Perchetti GA, Zhu H, Mills MG, et al. Specific allelic discrimination of N501Y and other SARS-CoV-2  
427 mutations by ddPCR detects B.1.1.7 lineage in Washington State. *medRxiv*. Published online March  
428 12, 2021:2021.03.10.21253321. doi:10.1101/2021.03.10.21253321
- 429 37. Haim-Boukobza S, Roquebert B, Trombert-Paolantoni S, et al. Early Release - Detecting Rapid  
430 Spread of SARS-CoV-2 Variants, France, January 26–February 16, 2021 - Volume 27, Number 5—  
431 May 2021 - Emerging Infectious Diseases journal - CDC. doi:10.3201/eid2705.210397

432 **TABLES**

433

434 **Table 1.** Patient Characteristics and Aggregate Genotyping RT-qPCR Screening Results During Study  
435 Period

436

Characteristic	All SARS-CoV-2 Infections	RT-qPCR Population	WGS Validation Subset
Patients	11,636	4,049	229
Age at First Positive NAAT	36 [23-52]	37 [23-53]	37 [23-52]
Female	6,009 (51.64%)	2,065 (51.00%)	128 (55.90%)
Initial Diagnostic Specimen	-	-	-
Month of Diagnosis	-	-	-
December 2020	6,074 (52.20%)	344 (8.50%)	18 (7.86%)
January 2021	4,381 (37.65%)	3,050 (75.33%)	170 (74.24%)
February 2021	1,119 (9.62%)	640 (15.80%)	37 (16.16%)
March 2021	62 (0.53%)	15 (0.37%)	4 (1.75%)
Specimen Collection Site	-	-	-
Outpatient COVID-19 Screening Site	6,187 (53.18%)	2,393 (59.10%)	138 (60.26%)
Emergency Department	2,633 (22.62%)	704 (17.39%)	34 (14.85%)
Outpatient Laboratory	1,190 (10.23%)	469 (11.58%)	24 (10.48%)
Occupational Health	628 (5.40%)	123 (3.04%)	6 (2.62%)
Outpatient Clinic	564 (4.85%)	210 (5.19%)	20 (8.73%)
Urgent Care	220 (1.89%)	75 (1.85%)	6 (2.62%)
Inpatient Floor	154 (1.32%)	55 (1.36%)	1 (0.43%)
Perioperative/Periprocedural	28 (0.24%)	11 (0.27%)	0 (0.00%)
Intensive Care Unit	20 (0.17%)	4 (0.10%)	0 (0.00%)
Infusion Center	10 (0.09%)	3 (0.07%)	0 (0.00%)
Home Healthcare	2 (0.02%)	2 (0.05%)	0 (0.00%)
Specimen Source	-	-	-
Nasopharyngeal Swab	6,607 (56.78%)	1,965 (48.51%)	115 (50.22%)
Mid-Turbinate Nasal Swab	4,893 (42.05%)	2,077 (51.30%)	111 (48.48%)
Other	136 (1.17%)	7 (0.17%)	3 (1.30%)
NAAT Platform	-	-	-
PerkinElmer-Based RT-qPCR	7,004 (60.19%)	2,798 (69.10%)	157 (68.56%)
Lab-Developed RT-qPCR	2,418 (20.78%)	610 (15.07%)	44 (19.21%)
Hologic Panther	1,219 (10.48%)	353 (8.72%)	25 (10.92%)
Cepheid GeneXpert	573 (4.92%)	147 (3.63%)	1 (0.44%)
Roche Liat	320 (2.75%)	97 (2.40%)	0 (0.00%)
Genmark Eplex	102 (0.88%)	44 (1.09%)	2 (0.87%)
RT-qPCR Genotype	-	-	-
L452, E484, N501	-	2,308 (57.00%)	120 (52.40%)
L452R, E484, N501	-	1,567 (38.70%)	70 (30.57%)
L452, E484K, N501	-	22 (0.54%)	14 (6.11%)
L452, E484, N501Y	-	34 (0.84%)	22 (9.61%)
L452, E484K, N501Y	-	3 (0.07%)	3 (1.30%)
Unable to Genotype <sup>a</sup>	-	115 (2.84%)	0 (0.00%)

NAAT, nucleic acid amplification test; WGS, whole genome next-generation sequencing

<sup>a</sup> Low viral load, amplification failure, or reaction set-up failure despite repeat.

437

438

439 **Table 2.** Genotyping RT-qPCR Validation Against Whole-Genome Next-Generation Sequencing  
440

RT-qPCR	Whole-Genome Next-Generation Sequencing					
	L452R		E484K		N501Y	
	Detected	Not Detected	Detected	Not Detected	Detected	Not Detected
<b>Detected</b>	67	3 <sup>a</sup>	17	0	25	0
<b>Not Detected</b>	0	159	0	212	0	204
<b>PPA (95% CI)<sup>b</sup></b>	100% (95-100%)	-	100% (80-100%)	-	100% (86-100%)	-
<b>NPA (95% CI)<sup>b</sup></b>	-	98% (95-99%)	-	100% (98-100%)	-	100% (98-100%)

CI, confidence interval; PPA, positive percent agreement; NPA, negative percent agreement.

<sup>a</sup> Three specimens positive for L452R by RT-qPCR but negative for L452R by sequencing. Further characterization of these samples provided in results.

<sup>b</sup> RT-qPCR relative to next-generation sequencing.

441

442 **Table 3.** PANGO Lineage Distribution of Screen-Detected Variants by RT-qPCR  
443

PANGO Lineage	RT-qPCR Genotype				
	L452R, E484, N501	L452, E484K, N501	L452, E484, N501Y	L452, E484K, N501Y	L452, E484, N501
B.1	2 (3)	2 (14)	1 (5)	0 (0)	14 (12)
B.1.1	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)
B.1.1.174	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
B.1.1.222	1 (1) <sup>a</sup>	0 (0)	0 (0)	0 (0)	1 (1)
B.1.1.228	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
P.2 <sup>b</sup>	0 (0)	11 (79)	0 (0)	0 (0)	0 (0)
B.1.1.291	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
B.1.1.368	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)
B.1.1.416	0 (0)	0 (0)	0 (0)	0 (0)	3 (3)
B.1.1.432	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
B.1.1.517	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
B.1.1.519	0 (0)	0 (0)	0 (0)	0 (0)	8 (7)
B.1.1.7 <sup>c</sup>	0 (0)	0 (0)	17 (77)	0 (0)	0 (0)
B.1.139	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)
B.1.2	1 (1) <sup>a</sup>	0 (0)	3 (14)	0 (0)	41 (34)
B.1.232	0 (0)	0 (0)	0 (0)	0 (0)	5 (4)
B.1.234	0 (0)	0 (0)	0 (0)	0 (0)	3 (3)
B.1.239	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
B.1.240	0 (0)	0 (0)	0 (0)	0 (0)	3 (3)
B.1.243	1 (1) <sup>a</sup>	0 (0)	0 (0)	0 (0)	6 (5)
B.1.265	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
B.1.311	0 (0)	0 (0)	0 (0)	0 (0)	6 (5)
B.1.323	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
B.1.351 <sup>c</sup>	0 (0)	0 (0)	0 (0)	3 (100)	0 (0)
B.1.361	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
B.1.369	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)
B.1.375	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)
B.1.427 <sup>c</sup>	42 (60)	0 (0)	0 (0)	0 (0)	0 (0)
B.1.429 <sup>c</sup>	23 (33)	0 (0)	0 (0)	0 (0)	0 (0)
B.1.453	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
B.1.480	0 (0)	0 (0)	1 (5)	0 (0)	0 (0)
B.1.526 <sup>b</sup>	0 (0)	1 (7)	0 (0)	0 (0)	0 (0)
B.1.561	0 (0)	0 (0)	0 (0)	0 (0)	4 (3)
B.1.565	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
B.1.568	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
B.1.577	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
B.1.596	0 (0)	0 (0)	0 (0)	0 (0)	2 (2)
B.1.599	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
<b>Total</b>	<b>70</b>	<b>14</b>	<b>22</b>	<b>3</b>	<b>120</b>

Data presented as n (column %)

<sup>a</sup> Three specimens positive for L452R by RT-qPCR but negative for L452R by next-generation sequencing.

<sup>b</sup> CDC-classified variants of interest

<sup>c</sup> CDC-classified variants of concern



445 **Table 4.** Local Epidemiologic Emergence of L452R  
446

<b>Week of Year, 2020-2021</b>	<b>Total New Infections Genotyped<sup>a</sup></b>	<b>L452R Infections</b>
Weeks 49-52: 2020-12-01 to 2020-12-31 <sup>b</sup>	476	118 (24.8%)
Week 1: 2021-01-01	905	300 (33.1%)
Week 2: 2021-01-08	888	330 (37.2%)
Week 3: 2021-01-15	598	267 (44.6%)
Week 4: 2021-01-22	329	141 (42.9%)
Week 5: 2021-01-29	265	145 (54.7%)
Week 6: 2021-02-05	199	102 (51.3%)
Week 7: 2021-02-12	120	70 (58.3%)
Week 8: 2021-02-19	106	64 (60.4%)
Week 9: 2021-02-26	48	30 (62.5%)
<b>Total</b>	<b>3,934</b>	<b>1,567 (39.8%)</b>

<sup>a</sup> Confirmed by nucleic acid amplification testing, with diagnosis date assigned by first positive test date.

<sup>b</sup> Grouped due to fewer tested specimens in early December 2020.

<sup>c</sup> Proportion of cases in each week positive for L452R.

447

448 **FIGURE LEGENDS**

449

450 **Figure 1.** Flow chart of specimens sent for nucleic acid amplification tests (NAAT) during the study period  
451 and number of specimens ultimately genotyped by multiplex RT-qPCR. \*Predominantly specimens with  
452 insufficient material, low viral load ( $C_t > 30$ , RLU  $< 1,100$ ) or positive specimens in December prior to  
453 universal institution-wide genotyping.

454

455 **Figure 2.** Nextclade phylogenetic tree of 2,130 SARS-CoV-2 genomes, including 225 of the 229  
456 sequenced genomes from this study, and 1,905 genomes from the Nextstrain global reference tree (left  
457 panel). There were 3 sequenced genomes excluded due to discordance between PCR and sequencing,  
458 and 1 genome excluded due to insufficient quality to assign a clade. The 225 included genomes are  
459 colored by RT-qPCR genotyping result, with each circle representing a sequenced genome. Branch  
460 length corresponds to nucleotide divergence. Arrowheads point to mutations identified either sporadically,  
461 or in rare lineages. Isolates with N501Y mutations predominantly belong to clade 20I/501Y.V1 and  
462 lineage B.1.1.7, though sporadic mutations are noted in clade 20G lineage B.1.2 (top three green  
463 arrowheads) and clade 20A lineage B.1.480 (bottom green arrowhead). In addition to the clade 20B  
464 lineage P.2 variant of concern, E484K RT-qPCR also identified a clade 20C lineage B.1.526 variant of  
465 interest (top two yellow arrowheads), as well as a clade 20A proposed lineage B.1 (bottom yellow  
466 arrowhead). Isolates with L452R mutation (turquoise) belong predominantly to clade 20C, and lineages  
467 B.1.429 and B.1.427 (right panel). Sporadic L452R mutation was noted within one sample belonging to  
468 clade 20A lineage B.1 (turquoise arrowhead). PANGO lineage names and Nextstrain clade names were  
469 assigned as of April 5, 2021.

470

471 **Figure 3.** Nextclade phylogenetic tree from Figure 2 magnified to visualize isolates with E484K mutations  
472 in clade 20B lineage P.2 (left panel), and isolates with combined N501Y+E484K mutations, all of which  
473 belong to clade 20H/501Y.V2 lineage B.1.351 (right panel). They are shown next to their nearest  
474 neighbors from the Nextstrain global reference tree, with branch length corresponding to nucleotide  
475 divergence. PANGO lineage names and Nextstrain clade names were assigned as of April 5, 2021.

476

477 **Figure 4.** Local epidemiologic emergence of L452R mutations in our genotyped population of 3,934 from  
478 December 2020 to March 2021. Bar plot and left y-axis represent number of new unique genotyped  
479 infections by week grouped by RT-qPCR-defined genotype. Scatter plot and right y-axis represents  
480 proportion of new unique genotyped infections with L452R genotype, with 95% Clopper-Pearson  
481 confidence interval.